As of 22 January, 19 of the 23 patients who have received treatment are still alive, with the longest evaluable survival ...

Eli Lilly and Company LLY announced that the FDA has granted a Breakthrough Therapy designation to its novel folate receptor ...

The FDA has granted breakthrough therapy designation (BTD) to sofetabart mipitecan (LY4170156) for the treatment of patients ...

Accrual in this trial was suspended in March 2025 as a result of findings from the Checkmate 8HW trial, which showed that the combination of nivolumab (Opdivo) and ipilimumab (Yervoy) significantly ...

The addition of tiragolumab to Tecentriq and Avastin did not significantly improve progression-free survival in hepatocellular carcinoma patients. Median progression-free survival was 8.3 months with ...

In the United States, ONS-5010/LYTENAVA™ (bevacizumab-vikg) is investigational. If approved in the United States, ONS-5010/LYTENAVA™, would be the first approved ophthalmic formulation of bevacizumab ...

Bevacizumab and erlotinib showed high efficacy in HLRCC-associated papillary renal-cell carcinoma, with a 72% response rate and median OS of 44.6 months. In sporadic papillary renal cell carcinoma, ...

INCHEON, South Korea--(BUSINESS WIRE)--Celltrion Healthcare announced today that the European Commission (EC) has approved Vegzelma™ (CT-P16), a biosimilar bevacizumab referencing EU-approved Avastin ...

ABSTRACT: The use of vascular endothelial growth factor (VEGF) inhibitors, particularly anti-VEGF agents like Bevacizumab, has become a cornerstone in the treatment of proliferative diabetic ...